<DOC>
	<DOCNO>NCT03010046</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled , ascend , single-infusion , sequential group study . Single , ascend dos administer approximately 56 subject , option 1 additional multi-dose cohort approximately 8 subject . The primary objective evaluate safety ANX005 administer intravenous infusion single agent combination intravenous immunoglobulin ( IVIg ) . The optional multi-dose cohort evaluate either additional subject maximum tolerate dose ANX005 administer 2 infusion .</brief_summary>
	<brief_title>Single Dose Study ANX005 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<criteria>Male female 18 year old Females must postmenopausal , surgically sterilize , willing able use 2 method contraception throughout study 1 month final study visit Willing able undergo vaccination vaccinate recently History autoimmune disease , meningitis , septicemia pneumonia History hypercoagulable disease , hyperviscosity , thrombosis , renal dysfunction acute renal failure Known genetic deficiency complement cascade system History condition whose symptom effect could alter protein catabolism IgG utilization , e.g . proteinlosing enteropathy nephrotic syndrome Body weight less 50 kg great 100 kg Hypersensitivity allergic reaction excipients ANX005 drug product ( Cohorts 4b 5b ) Known selective IgA deficiency presence antibody IgA screening ( Cohorts 4b 5b ) Prior reaction hypersensitivity blood product , include IVIg excipients IVIg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>